Pages that link to "Q33947635"
Jump to navigation
Jump to search
The following pages link to Identification of an acquired JAK2 mutation in polycythemia vera (Q33947635):
Displaying 50 items.
- Conditional deletion of Jak2 reveals an essential role in hematopoiesis throughout mouse ontogeny: implications for Jak2 inhibition in humans (Q21133609) (← links)
- Phosphorylation of p27Kip1 by JAK2 directly links cytokine receptor signaling to cell cycle control (Q24297854) (← links)
- Janus kinases in immune cell signaling (Q24322021) (← links)
- The molecular mechanisms that control thrombopoiesis (Q24536138) (← links)
- JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis (Q24609999) (← links)
- Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies (Q24648438) (← links)
- Therapeutic targeting of Janus kinases (Q24658483) (← links)
- Erythropoietin stimulates phosphorylation and activation of GATA-1 via the PI3-kinase/AKT signaling pathway (Q24685447) (← links)
- Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth (Q24685474) (← links)
- Potential Role of JAK-STAT Signaling Pathway in the Neurogenic-to-Gliogenic Shift in Down Syndrome Brain (Q26765647) (← links)
- Targeting JAK2 in the therapy of myeloproliferative neoplasms (Q26860796) (← links)
- The azaindole framework in the design of kinase inhibitors (Q27013668) (← links)
- Signal transduction in the chronic leukemias: implications for targeted therapies (Q27026031) (← links)
- Janus kinase inhibitors: jackpot or potluck? (Q27027230) (← links)
- The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia (Q27266125) (← links)
- A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms (Q27851467) (← links)
- The treatment of polycythaemia vera: an update in the JAK2 era (Q28212560) (← links)
- An unconventional antigen translated by a novel internal ribosome entry site elicits antitumor humoral immune reactions (Q28264336) (← links)
- Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms (Q28271752) (← links)
- Quantitative histological image analyses of reticulin fibers in a myelofibrotic mouse (Q28364884) (← links)
- Receptor specific downregulation of cytokine signaling by autophosphorylation in the FERM domain of Jak2 (Q28506187) (← links)
- Differential biological activity of disease-associated JAK2 mutants (Q28508045) (← links)
- Efficacious intermittent dosing of a novel JAK2 inhibitor in mouse models of polycythemia vera (Q28729862) (← links)
- Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signaling (Q28741023) (← links)
- Mouse models of myeloproliferative neoplasms: JAK of all grades (Q28744478) (← links)
- Splenectomy normalizes hematocrit in murine polycythemia vera (Q28751387) (← links)
- Advances in understanding cancer genomes through second-generation sequencing (Q30014827) (← links)
- JAK2 (V617F) Positive Latent Myeloproliferative Neoplasm Presenting with Splanchnic Vein Thrombosis (Q30303071) (← links)
- A data-driven network model of primary myelofibrosis: transcriptional and post-transcriptional alterations in CD34+ cells. (Q31110460) (← links)
- Novel tumor antigens elicit anti-tumor humoral immune reactions in a subset of patients with polycythemia vera (Q33264010) (← links)
- JAK2 V617F in myeloid disorders: what do we know now, and where are we headed? (Q33341856) (← links)
- Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis (Q33386057) (← links)
- Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis (Q33400570) (← links)
- Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib (Q33402522) (← links)
- Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies (Q33437478) (← links)
- Structural effects of clinically observed mutations in JAK2 exons 13-15: comparison with V617F and exon 12 mutations (Q33501856) (← links)
- Design and evaluation of a real-time PCR assay for quantification of JAK2 V617F and wild-type JAK2 transcript levels in the clinical laboratory (Q33555643) (← links)
- Human-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders (Q33560423) (← links)
- Jak2 inhibitors: rationale and role as therapeutic agents in hematologic malignancies (Q33586552) (← links)
- AKT is a therapeutic target in myeloproliferative neoplasms (Q33623277) (← links)
- Transforming JAK1 mutations exhibit differential signalling, FERM domain requirements and growth responses to interferon-γ (Q33702627) (← links)
- Pathological interactions between hematopoietic stem cells and their niche revealed by mouse models of primary myelofibrosis (Q33753094) (← links)
- Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells. (Q33788708) (← links)
- Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis (Q33788714) (← links)
- Detection of exon 12 Mutations in the JAK2 gene: enhanced analytical sensitivity using clamped PCR and nucleotide sequencing (Q33813824) (← links)
- Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease (Q33839857) (← links)
- Making sense of cancer genomic data (Q33846850) (← links)
- Mechanistic insights into activation and SOCS3-mediated inhibition of myeloproliferative neoplasm-associated JAK2 mutants from biochemical and structural analyses (Q33857008) (← links)
- Activation of JAK2-V617F by components of heterodimeric cytokine receptors (Q33883366) (← links)
- Differential sensitivity to JAK inhibitory drugs by isogenic human erythroblasts and hematopoietic progenitors generated from patient-specific induced pluripotent stem cells (Q33894805) (← links)